Bereich
Rheumatologie
RHEUMA · Dept. I
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlenen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology (Oxford) 2017; 56:1579-1585.
01.09.2017Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
01.09.2017Rheumatology (Oxford) 2017; 56:1579-1585
Alpizar-Rodriguez Deshiré, Gabay Cem, Courvoisier Delphine S, Lamacchia Céline, Mahler Michael, Roux-Lombard Pascale, Von Mühlenen Ines, Walker Ulrich A, Kyburz Diego, Zufferey Pascal, Ciurea Adrian, Dudler Jean, Möller Burkhard, Müller Rüdiger, Finckh Axel
Treatment with Biologicals in Rheumatoid Arthritis: An Overview
Rein P, Müller R. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatology and Therapy 2017; 4:247-261.
22.08.2017Treatment with Biologicals in Rheumatoid Arthritis: An Overview
22.08.2017Rheumatology and Therapy 2017; 4:247-261
Rein Philipp, Müller Rüdiger
Treatment with Biologicals in Rheumatoid Arthritis: An Overview
Rein P, Müller R. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatol Ther 2017; 4:247-261.
22.08.2017Treatment with Biologicals in Rheumatoid Arthritis: An Overview
22.08.2017Rheumatol Ther 2017; 4:247-261
Rein Philipp, Müller Rüdiger
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017; 36:2187-2192.
03.08.2017Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
03.08.2017Clin Rheumatol 2017; 36:2187-2192
Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017; 36:2187-2192.
03.08.2017Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
03.08.2017Clin Rheumatol 2017; 36:2187-2192
Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes
Blue-Finger-Syndrome and Tofacitinib
Popp F, Benecke U, Fischer S, von Kempis J, Koeger P, Müller R. Blue-Finger-Syndrome and Tofacitinib - Case Report. Clinical Image: Annals of Clinical Case Reports 2017; 2
18.07.2017Blue-Finger-Syndrome and Tofacitinib
18.07.2017Clinical Image: Annals of Clinical Case Reports 2017; 2
Popp Florian, Benecke U, Fischer S, von Kempis Johannes, Koeger P, Müller Rüdiger
A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement
Rubbert-Roth A, Jacobs J, Bijlsma J, Welsing P. A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement. Ann Rheum Dis 2017; 77:1085-1086.
23.06.2017A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement
23.06.2017Ann Rheum Dis 2017; 77:1085-1086
Rubbert-Roth Andrea, Jacobs Johannes W G, Bijlsma Johannes W J, Welsing Paco M J
Granuloma Annulare, Drug-Induced Lupus and
Popp F, Fischer S, Kempf W, von Kempis J, Welcker M, Müller R. Granuloma Annulare, Drug-Induced Lupus and - Case Report. Clinical Image: Annals of Clinical Case Reports 2017; 2
17.04.2017Granuloma Annulare, Drug-Induced Lupus and
17.04.2017Clinical Image: Annals of Clinical Case Reports 2017; 2
Popp Florian, Fischer S, Kempf W, von Kempis Johannes, Welcker M, Müller Rüdiger
Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
Chaigne B, Ribi C, von Kempis J, Stoll T, Dayer E, Huynh-Do U, Trendelenburg M, Perneger T, Chizzolini C, Swiss Systemic Lupus Erythematosus Cohort Study Group. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol 2017; 18:17.
28.03.2017Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
28.03.2017BMC Immunol 2017; 18:17
Chaigne Benjamin, Ribi Camillo, von Kempis Johannes, Stoll Thomas, Dayer Eric, Huynh-Do Uyen, Trendelenburg Marten, Perneger Thomas, Chizzolini Carlo, Swiss Systemic Lupus Erythematosus Cohort Study Group
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlenen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clin Rheumatol 2017
21.01.2017The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
21.01.2017Clin Rheumatol 2017
Alpizar-Rodriguez D, Bas Sylvette, Gascon Danielle, Lamacchia Céline, Roux-Lombard Pascale, Lauper Kim, Nissen Michael J, Courvoisier Delphine S, Gabay Cem, Mahler Michael, Zufferey Pascal, Brulhart Laure, Müller Rüdiger, Möller Burkhard, Dudler Jean, Ciurea Adrian, Walker Ulrich A, Von Mühlenen Ines, Kyburz Diego, Finckh Axel
T Cells of Infants Are Mature, but Hyporeactive Due to Limited Ca2+ Influx
Schmiedeberg K, Krause H, Röhl F, Hartig R, Jorch G, Brunner-Weinzierl M. T Cells of Infants Are Mature, but Hyporeactive Due to Limited Ca2+ Influx. PloS one 2016; 11:e0166633.
28.11.2016T Cells of Infants Are Mature, but Hyporeactive Due to Limited Ca2+ Influx
28.11.2016PloS one 2016; 11:e0166633
Schmiedeberg Kristin, Krause Hardy, Röhl Friedrich-Wilhelm, Hartig Roland, Jorch Gerhard, Brunner-Weinzierl Monika C
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
Müller R, von Kempis J, Spaeth M, Schiff M, Schulze-Koops H, Haile S, Finckh A, Kaegi T, Reshiti N. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clin Rheumatol 2016; 36:59-66.
12.11.2016Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
12.11.2016Clin Rheumatol 2016; 36:59-66
Müller Rüdiger, von Kempis Johannes, Spaeth Michael, Schiff Michael, Schulze-Koops Hendrik, Haile Sarah R, Finckh Axel, Kaegi Toni, Reshiti Nazim
Handheld single photon emission computed tomography (handheld SPECT) navigated video-assisted thoracoscopic surgery of computer tomography-guided radioactively marked pulmonary lesions
Müller J, Putora P, Schneider T, Zeisel C, Brutsche M, Bartz-Batliner M, Markus A, Kick J. Handheld single photon emission computed tomography (handheld SPECT) navigated video-assisted thoracoscopic surgery of computer tomography-guided radioactively marked pulmonary lesions. Interact Cardiovasc Thorac Surg 2016; 23:345-350.
20.05.2016Handheld single photon emission computed tomography (handheld SPECT) navigated video-assisted thoracoscopic surgery of computer tomography-guided radioactively marked pulmonary lesions
20.05.2016Interact Cardiovasc Thorac Surg 2016; 23:345-350
Müller Joachim, Putora Paul Martin, Schneider Tino, Zeisel C, Brutsche Martin, Bartz-Batliner Mira, Markus Alexander, Kick Jochen
Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Res Ther 2016; 18:88.
14.04.2016Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
14.04.2016Arthritis Res Ther 2016; 18:88
Müller Rüdiger, Gengenbacher Michael, Richter Symi, Dudler Jean, Möller Burkhard, von Kempis Johannes
Postoperative Fasziendehiszenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept
Müller R. Postoperative Fasziendehiszenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept. Swiss Medical Forum 2016; 15:114-115.
19.01.2016Postoperative Fasziendehiszenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept
19.01.2016Swiss Medical Forum 2016; 15:114-115
Müller Rüdiger
Jaundice after Herbage Walking Tour of a 44 Year Old Man
Sawatzki M, Haller C, Henz S. Jaundice after Herbage Walking Tour of a 44 Year Old Man. Praxis Schweizerische Rundschau für Medizin 2015; 104:635-637.
03.06.2015Jaundice after Herbage Walking Tour of a 44 Year Old Man
03.06.2015Praxis Schweizerische Rundschau für Medizin 2015; 104:635-637
Sawatzki Mikael, Haller Christoph, Henz Samuel
[Jaundice after Herbage Walking Tour of a 44 Year Old Man]
Sawatzki M, Haller C, Henz S. [Jaundice after Herbage Walking Tour of a 44 Year Old Man]. Praxis (Bern 1994) 2015; 104:635-7.
03.06.2015[Jaundice after Herbage Walking Tour of a 44 Year Old Man]
03.06.2015Praxis (Bern 1994) 2015; 104:635-7
Sawatzki Mikael, Haller Christoph, Henz Samuel
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
Müller R, von Kempis J, Haile S, Schiff M. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum 2015; 45:28-34.
03.03.2015Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
03.03.2015Semin Arthritis Rheum 2015; 45:28-34
Müller Rüdiger, von Kempis Johannes, Haile Sarah, Schiff Michael H
The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland
Ribi C, Chizzolini C, von Kempis J, Stoll T, Spertini F, Otto P, Koenig K, Lindner G, Leimgruber A, Hunziker T, Hauser T, Eisenberger U, Dayer E, Cohen C, Gayet-Ageron A, Trendelenburg M, Swiss Systemic Lupus Erythematosus Cohort Study Group. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Med Wkly 2014; 144:w13990.
07.08.2014The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland
07.08.2014Swiss Med Wkly 2014; 144:w13990
Ribi Camillo, Chizzolini Carlo, von Kempis Johannes, Stoll Thomas, Spertini François, Otto Petra, Koenig Katrin, Lindner Gregor, Leimgruber Annette, Hunziker Thomas, Hauser Thomas, Eisenberger Ute, Dayer Eric, Cohen Clemens, Gayet-Ageron Angèle, Trendelenburg Marten, Swiss Systemic Lupus Erythematosus Cohort Study Group
The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis
Müller R, Schiff M, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, Swiss Clinical Quality Management (SCQM) physicians. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clin Rheumatol 2014; 34:51-9.
15.07.2014The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis
15.07.2014Clin Rheumatol 2014; 34:51-9
Müller Rüdiger, Schiff M, Kaegi T, Finckh A, Haile Sarah, Schulze-Koops H, von Kempis Johannes, Swiss Clinical Quality Management (SCQM) physicians